Market Closed -
London S.E.
09:05:24 03/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
24.25
GBX
|
-3.96%
|
|
-7.62%
|
-59.24%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13.36
|
17.02
|
191.6
|
137.8
|
85.09
|
25.91
|
-
|
-
|
Enterprise Value (EV)
1 |
13.36
|
17.02
|
191.6
|
133.6
|
84.09
|
27.36
|
27.99
|
48.38
|
P/E ratio
|
-8.7
x
|
-17.5
x
|
-115
x
|
-63.3
x
|
-26.6
x
|
-5.14
x
|
-6.68
x
|
0.64
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
471
x
|
-
|
0.6
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
497
x
|
-
|
1.12
x
|
EV / EBITDA
|
-
|
-
|
-
|
-51.8
x
|
-20.7
x
|
-8.68
x
|
-8.62
x
|
1.42
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-25.7
x
|
-11.9
x
|
-14
x
|
2.37
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-3.88%
|
-8.41%
|
-7.15%
|
42.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,427
|
64,835
|
66,657
|
68,069
|
68,069
|
1,06,839
|
-
|
-
|
Reference price
2 |
0.2175
|
0.2625
|
2.875
|
2.025
|
1.250
|
0.2425
|
0.2425
|
0.2425
|
Announcement Date
|
15/10/19
|
12/10/20
|
25/10/21
|
24/10/22
|
09/10/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.055
|
-
|
43.15
|
EBITDA
1 |
-
|
-
|
-
|
-2.578
|
-4.065
|
-3.154
|
-3.248
|
33.99
|
EBIT
1 |
-1.686
|
-
|
-1.718
|
-2.58
|
-4.066
|
-4.154
|
-3.2
|
34
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-7,552.73%
|
-
|
78.8%
|
Earnings before Tax (EBT)
1 |
-1.682
|
-
|
-1.718
|
-2.579
|
-4.025
|
-4.146
|
-3.2
|
34
|
Net income
1 |
-1.452
|
-0.9859
|
-1.5
|
-2.172
|
-3.192
|
-3.396
|
-2.6
|
27.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-6,175.45%
|
-
|
63.04%
|
EPS
2 |
-0.0250
|
-0.0150
|
-0.0250
|
-0.0320
|
-0.0470
|
-0.0472
|
-0.0363
|
0.3800
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-3.267
|
-2.3
|
-2
|
20.4
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-4,181.82%
|
-
|
47.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
60.02%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
75%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/10/19
|
12/10/20
|
25/10/21
|
24/10/22
|
09/10/23
|
-
|
-
|
-
|
Fiscal Period: Juni |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
1.45
|
2.08
|
22.5
|
Net Cash position
1 |
-
|
-
|
-
|
4.26
|
0.99
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.4609
x
|
-0.641
x
|
0.6612
x
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-3.27
|
-2.3
|
-2
|
20.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-0.0300
|
-
|
-0.0300
|
-0.0300
|
0.2800
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
0
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
1.82%
|
-
|
-
|
Announcement Date
|
15/10/19
|
12/10/20
|
25/10/21
|
24/10/22
|
09/10/23
|
-
|
-
|
-
|
Last Close Price
0.2425
GBP Average target price
1.76
GBP Spread / Average Target +625.77% Consensus |
1st Jan change
|
Capi.
|
---|
| -59.24% | 32.52M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|